- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01140334
Treatment for Psychological and Drug Abuse Problems
19 september 2013 uppdaterad av: Michael Kidorf, Johns Hopkins University
Maximizing Effectiveness of Integrated Treatment Approaches
The purpose of the study is to evaluate methods to help people in substance abuse treatment receive better psychiatric care.
Patients enrolled in the study will be offered three months of standard psychiatric treatment, which consists of weekly individual counseling and group counseling, as well as regular appointments with a psychiatrist.
Patients will be randomly assigned to standard psychiatric care or standard psychiatric care plus voucher incentives.
These incentives can be earned by successfully attending all scheduled psychiatric appointments each week.
The investigators expect that patients in the voucher condition will attend more psychiatric sessions, which will lead to greater reductions in psychiatric distress.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Male and female opioid-dependent patients at Addiction Treatment Services with any current psychiatric disorder (N = 100) will be randomly assigned to one of two psychiatric service conditions: 1) reinforced on-site integrated care (ROIC), with voucher incentives contingent on attending weekly psychiatric sessions; or 2) standard on-site integrated care (SOIC).
Participants in both conditions will receive access to the same schedule and range of psychiatric and substance abuse treatment services.
Participants will be assessed for 3-months post-randomization to determine rates of service utilization and adherence to psychiatric care, changes in scope and severity of psychiatric and psychosocial problems, and rates of drug use and treatment retention.
Positive findings would have considerable heuristic and health care policy and practice implications.
The entire study, including dissemination of the major findings at a national meeting and submission of the first manuscript, is designed to be completed within 2-years.
Studietyp
Interventionell
Inskrivning (Faktisk)
158
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21224
- Addiction Treatment Services
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- At least 18 years of age
- Voluntarily seeking psychiatric treatment
- Meets DSM-IV criteria for opiate dependence
- Meets FDA/CSAT guidelines for methadone maintenance
- Meets DSM-IV criteria for at least one current psychiatric disorder
Exclusion Criteria:
- Pregnancy
- Onset or acute exacerbation of a medical illness requiring immediate and intense care
- An organic mental disorder (e.g., delirium, dementia)
- Current participation in psychiatric care
- Mandatory psychiatric treatment
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Reinforced On-Site Integrated Care (ROIC)
Patients assigned to this condition will be treated at ATS for psychological problems.
They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor.
They will also be referred to attend group therapy one time per week.
In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
|
Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions.
These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments.
Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant.
The maximum amount of voucher earnings over the study is $300.
|
|
Aktiv komparator: Standard On-Site Integrated Care (SOIC).
Patients assigned to this condition will be treated at ATS for psychological problems.
They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor.
They will also be referred to attend group therapy one time per week.
|
Patients assigned to this condition will be treated at ATS for psychological problems.
They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor.
They will also be referred to attend group therapy one time per week.
No voucher incentive will be offered in this condition.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Psychiatric Treatment Adherence
Tidsram: Weekly for 12 weeks
|
Patient adherence to all scheduled psychiatric sessions (i.e.
individual, group, psychiatrist) will be measured weekly for 12 weeks.
|
Weekly for 12 weeks
|
|
Level of Psychiatric Distress
Tidsram: Every 4-weeks for 12 weeks
|
Patients will complete the Addiction Severity Index (ASI) and the SCL-90 every 4-weeks, for 12-weeks, to measure their current levels of psychiatric distress.
|
Every 4-weeks for 12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Psychiatric Medication Adherence
Tidsram: Every 4-weeks
|
Patients will complete a Medication-Taking Scale every 4-weeks to assess their adherence to prescribed psychiatric medications.
|
Every 4-weeks
|
|
Substance Use
Tidsram: Weekly for 12-weeks
|
Patients are required to leave weekly urine specimens (for 12-weeks) which are tested for drugs of abuse (opioids, cocaine, benzodiazepines).
|
Weekly for 12-weeks
|
|
Treatment Retention
Tidsram: Weekly for 12-weeks
|
The length of time subjects remain in treatment is tracked throughout the study.
|
Weekly for 12-weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Michael Kidorf, Ph.D., Johns Hopkins University
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2009
Primärt slutförande (Faktisk)
1 augusti 2012
Avslutad studie (Faktisk)
1 augusti 2012
Studieregistreringsdatum
Först inskickad
3 juni 2010
Först inskickad som uppfyllde QC-kriterierna
8 juni 2010
Första postat (Uppskatta)
9 juni 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
20 september 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
19 september 2013
Senast verifierad
1 september 2013
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1RC1DA028154-01 (U.S.S. NIH-anslag/kontrakt)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .